Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee
Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 11, 2007--Amgen
(NASDAQ:AMGN) is presenting data today on the appropriate use of
Erythropoiesis Stimulating Agents (ESAs) in Chronic Renal Failure
(CRF) patients to a joint meeting of U.S. Food and Drug Administration
(FDA) advisory committees.
Amgen's presentation reviews data demonstrating that ESAs are safe
when used appropriately and explains the critical role ESAs play in
managing the debilitating effects of anemia in CRF patients. The
company's presentation recognizes the potential risks observed in
recent experimental trials targeting higher-than-recommended
hemoglobin levels, lays out the need for an appropriate hemoglobin
target of 10-12 g/dL to guide treatment and manage risk, and
highlights the importance of the ongoing Trial to Reduce
Cardiovascular Events with Aranesp Therapy (TREAT) to provide answers
on the impact of anemia treatment in CRF patients. The company also
identifies areas for future study and presents data that suggests that
patient response is a stronger risk factor for poor outcomes than ESA
"ESA treatment changed the lives of CRF patients by filling an
unmet medical need for a very sick population of dialysis patients,"
said Allen R. Nissenson, M.D., professor of medicine, associate dean,
and director of the Dialysis Program at the University of California,
Los Angeles (UCLA). "ESA treatment reduced the need for potentially
problematic blood transfusions and improved patient exercise ability,
physical functions and symptoms of anemia. As we continue evaluating
the appropriate use of ESA therapy, it's vital to remember the
patients. It's hard to overstate how sick these patients are and how
vulnerable they can be to changes in treatment."
Amgen's ESA products Aranesp(R) (darbepoetin alfa) and EPOGEN(R)
(Epoetin alfa) have been used in more than 2.2 million CRF patients.
Target Hemoglobin Range
"Physicians tell us that to optimally treat anemia in CRF patients
they need a hemoglobin target range to guide ESA dosing decisions,"
said Preston Klassen, M.D., executive director, Clinical Development,
Amgen. "In response to recent safety signals, Amgen is proposing a
conservative hemoglobin target range of 10 to 12 g/dL based on
clinical trial data, dialysis population surveillance data and nearly
two decades of clinical experience."
In the 1980's, double-blind, randomized, placebo-controlled
registrational clinical trials targeting a hemoglobin range between
10.7-12.7 g/dL showed that use of EPOGEN virtually eliminated the need
for blood transfusions in dialysis patients. Amgen will discuss with
the advisory committee data from these randomized clinical trials that
also shows the impact of EPOGEN on improving exercise capacity and
A hemoglobin target range of 10-12 g/dL was included in the
product labeling for EPOGEN from 1992 to 2007. In March 2007,
following the publication of clinical trial results that highlighted
safety concerns when ESAs are used to target hemoglobin levels of
greater than 13 g/dL, the FDA and Amgen announced the addition of a
black box safety warning to all ESA labels. The concept of a
hemoglobin target range was removed from ESA labeling at this time.
In response to new data the National Kidney Foundation conducted a
comprehensive review of all ESA clinical trials in CRF and in August
2007 updated its clinical practice guidelines for Anemia Management to
state that "the selected hemoglobin target should generally be in the
range 11 to 12 g/dL."
Recent Emphasis on Poorly Responsive Patients
Recent analyses of previous clinical trials has led to a focus on
a subset of CRF patients whose changing health status results in
transient periods of poor responsiveness to ESA therapy. In clinical
trials, worse outcomes have been reported in this subset of patients,
who are often described as "hyporesponders."
Poor responders appear to have a greater underlying burden of
illness resulting in greater risk of mortality. ESA responsiveness
reflects underlying health status and is a better predictor of
clinical risk than ESA dose alone.
"Amgen welcomes discussion with FDA on potential study designs to
explore approaches to dosing that will provide optimal anemia
management in this subset of very ill patients," explained Dr.
Questions about higher doses
Some analyses have shown that higher ESA doses are associated with
poor outcomes. However, Amgen noted that it is difficult to determine
if higher doses cause worse outcomes, or if higher doses are observed
in patients who are poor responders because of worse health status.
"Generally patients with poor ESA responsiveness and who receive
the highest ESA doses have very poor health status and suffer from
multiple co-morbid illnesses," said Dr. Klassen. "It would be expected
that these patients would have worse clinical outcomes."
Amgen will discuss with the FDA potential study designs to further
explore optimal anemia management in these patients.
Amgen will provide an update on the ongoing TREAT trial that will
investigate important questions about the potential survival
advantages of ESA therapy in CRF patients. TREAT is a 4,000-patient,
global multi-center, randomized, double-blind, placebo-controlled
trial to determine the impact of anemia therapy on mortality and
cardiovascular morbidity in patients with CKD and type 2 diabetes.
Amgen's full presentation and briefing materials submitted to the
joint meeting of the Cardiovascular and Renal Drugs Advisory (CRDAC)
and Drug Safety and Risk Management Advisory (DSRM) Committees are
available at www.amgen.com.
Amgen launched EPOGEN(R), one of the first biologically derived
human therapeutics, into the U.S. medical marketplace in 1989 for the
treatment of anemia in patients with chronic renal failure on
dialysis. EPOGEN is a recombinant protein with the same mechanism of
action as endogenous human erythropoietin, a protein produced by the
kidneys to stimulate the production of oxygen-transporting red blood
Aranesp(R) was approved by the U.S. Food and Drug Administration
(FDA) in September 2001 for the treatment of anemia associated with
chronic renal failure (CRF), for patients on dialysis and patients not
on dialysis. In July 2002, the FDA approved weekly dosing of Aranesp
for the treatment of anemia caused by concomitantly administered
chemotherapy in patients with nonmyeloid malignancies and in March
2006, the FDA approved every-three-week dosing in these patients.
Important Safety Information Including Boxed WARNINGS
Use the lowest dose of Aranesp(R) or EPOGEN(R) that will gradually
increase the hemoglobin concentration to the lowest level sufficient
to avoid the need for red blood cell transfusion.
Aranesp, EPOGEN and other erythropoiesis-stimulating agents (ESAs)
increased the risk for death and for serious cardiovascular events
when administered to target a hemoglobin of greater than 12 g/dL.
Cancer Patients: Use of ESAs:
- shortened the time to tumor progression in patients with
advanced head and neck cancer receiving radiation therapy when
administered to target a hemoglobin of greater than 12 g/dL;
- shortened overall survival and increased deaths attributed to
disease progression at 4 months in patients with metastatic
breast cancer receiving chemotherapy when administered to
target a hemoglobin of greater than 12 g/dL;
- increased the risk of death when administered to target a
hemoglobin of 12 g/dL in patients with active malignant
disease receiving neither chemotherapy nor radiation therapy.
ESAs are not indicated for this population.
Patients receiving ESAs pre-operatively for reduction of
allogeneic red blood cell transfusions: A higher incidence of deep
venous thrombosis was documented in patients receiving Epoetin alfa
who were not receiving prophylactic anticoagulation. Antithrombotic
prophylaxis should be strongly considered when Epoetin alfa is used to
reduce allogeneic red blood cell transfusions. Aranesp(R) is not
approved for this indication.
Aranesp and EPOGEN are contraindicated in patients with
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in Amgen's Form 10-K for the year ended
Dec. 31, 2006, and in Amgen's periodic reports on Form 10-Q and Form
8-K. Amgen is providing this information as of the date of this news
release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. The Company's results may
be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments (domestic or foreign) involving current and
future products, sales growth of recently launched products,
competition from other products (domestic or foreign), difficulties or
delays in manufacturing our products. In addition, sales of our
products are affected by reimbursement policies imposed by third-party
payors, including governments, private insurance plans and managed
care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward
managed care and health care cost containment as well as U.S.
legislation affecting pharmaceutical pricing and reimbursement.
Government and others' regulations and reimbursement policies may
affect the development, usage and pricing of our products.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and foreign
government regulatory authorities. The length of time that it takes
for Amgen to complete clinical trials and obtain regulatory approval
for product marketing has in the past varied and Amgen expects similar
variability in the future. We or others could identify safety, side
effects or manufacturing problems with our products after they are on
the market. Our business may be impacted by government investigations,
litigation and products liability claims. Further, while we routinely
obtain patents for our products and technology, the protection offered
by our patents and patent applications may be challenged, invalidated
or circumvented by our competitors. We depend on third parties for a
significant portion of our manufacturing capacity for the supply of
certain of our current and future products and limits on supply may
constrain sales of certain of our current products and product
candidate development. In addition, we compete with other companies
with respect to some of our marketed products as well as for the
discovery and development of new products. Discovery or identification
of new product candidates cannot be guaranteed and movement from
concept to product is uncertain and Amgen cannot guarantee that it
will be able to produce commercially successful products or maintain
the commercial success of Amgen's existing products. Amgen's stock
price may be affected by actual or perceived market opportunity,
competitive position, and success or failure of Amgen's products or
product candidates. Further, the discovery of significant problems
with a product similar to one of Amgen's products that implicate an
entire class of products could have a material adverse effect on sales
of the affected products and on Amgen's business and results of
operations. Further, some raw materials, medical devices and component
parts for our products are supplied by sole third-party suppliers.
Aranesp prescribing information can be accessed by calling
800-772-6436 or by logging on to www.aranesp.com.
CONTACT: Amgen, Washington, D.C.
Kelley Davenport, 202-585-9637 (media)
Amgen, Thousand Oaks
Emma Hurley, 310-849-1912 (media)
Arvind Sood, 805-447-1060 (investors)